Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Accumulated Expenses data on file, last reported at $13.9 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $13.9 million, down 30.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.9 million (down 30.16% YoY), and the FY2025 annual result was $16.5 million, down 30.0% from the prior year.
• Accumulated Expenses slipped to $13.9 million in Q1 2026 per CRBU's latest filing, from $16.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $25.4 million in Q3 2024 and troughed at $100000.0 in Q1 2022.
• A 5-year average of $16.5 million and a median of $18.2 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses tumbled 98.5% in 2022, then jumped 12444.0% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $16.1 million in 2022, then jumped by 31.44% to $21.1 million in 2023, then increased by 11.76% to $23.6 million in 2024, then slipped by 30.0% to $16.5 million in 2025, then declined by 16.0% to $13.9 million in 2026.
• Business Quant data shows CRBU's Accumulated Expenses at $13.9 million in Q1 2026, $16.5 million in Q4 2025, and $19.3 million in Q3 2025.